{
    "id": 1182,
    "fullName": "BRCA2 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BRCA2 mutant indicates an unspecified mutation in the BRCA2 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 675,
        "geneSymbol": "BRCA2",
        "terms": [
            "BRCA2",
            "BRCC2",
            "BROVCA2",
            "FACD",
            "FAD",
            "FAD1",
            "FANCD",
            "FANCD1",
            "GLM3",
            "PNCA2",
            "XRCC11"
        ]
    },
    "variant": "mutant",
    "createDate": "07/28/2014",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20813,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Zejula (niraparib) treatment resulted in a partial response with a median response duration of 387 days in 40% (8/20) of patients with BRCA1- or BRCA2-mutated ovarian or primary peritoneal cancer (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9005,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (NOVA), maintenance Zejula (niraparib) therapy significantly improved median progression-free survival compared to placebo (21.0 vs. 5.5 months, HR=0.27) in patients with platinum-sensitive, recurrent ovarian cancer harboring germline BRCA mutations (PMID: 27717299; NCT01847274).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6850,
                    "pubMedId": 27717299,
                    "title": "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27717299"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6875,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Veliparib (ABT-888) in combination with Platinol (cisplatin) and Navelbine (vinorelbine) resulted in a greater complete response (7%, 1/14), partial response (50%, 7/14), and 6-month progression free survival rate (71%, 10/14) in Erbb2 (Her2) negative breast cancer patients harboring germline BRCA1 or BRCA2 mutations compared to BRCA wild-type patients (PMID: 26801247).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 4286,
                "therapyName": "Cisplatin + Veliparib + Vinorelbine",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5936,
                    "pubMedId": 26801247,
                    "title": "Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26801247"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20810,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Zejula (niraparib) treatment resulted in stable disease for 175 days in a patient with non-small cell lung cancer harboring a BRCA2 mutation (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7531,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 11% (1/9) and stable disease in 67% (6/9) of ovarian cancer patients harboring germline mutations in BRCA1 or BRCA2 (PMID: 26842236).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 3314,
                "therapyName": "Irinotecan + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6398,
                    "pubMedId": 26842236,
                    "title": "Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26842236"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20389,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (PAOLA-1) trial, addition of maintenance Lynparza (olaparib) to Avastin (bevacizumab) improved median progression-free survival (mPFS) compared to placebo (22.1 vs 16.6 mo, HR=0.59, p<0.001) in patients with advanced ovarian cancer receiving standard first-line therapy, mPFS was significantly improved (37.2 vs 17.7 mo, HR=0.33) in patients with tumors harboring homologous-recombination deficiency, including BRCA mutations (PMID: 31851799; NCT02477644).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 9297,
                "therapyName": "Bevacizumab + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17826,
                    "pubMedId": 31851799,
                    "title": "Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31851799"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 21196,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Lynparza (olaparib) and Avastin (bevacizumab) combination therapy is included in guidelines as maintenance therapy for ovarian cancer patients harboring germline or somatic BRCA1/2 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 9297,
                "therapyName": "Bevacizumab + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17476,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Lynparza (olaparib) is included in guidelines for breast cancer patients with BRCA mutations who progressed on endocrine therapy and were previously treated with an anthracycline with or without a taxane (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1055,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 mutations (PMID: 20609467).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 770,
                    "pubMedId": 20609467,
                    "title": "Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20609467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11981,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BGB-290 treatment resulted in an improved objective response rate in ovarian cancer patients harboring germline BRCA1/2 mutations (58%, 7/12) compared to BRCA1/2 wild-type (25%, 2/8) patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 368PD; NCT02361723).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 2947,
                "therapyName": "Pamiparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9945,
                    "pubMedId": null,
                    "title": "Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17486,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Lynparza (olaparib) is included in guidelines for triple-receptor negative breast cancer patients with BRCA mutations who were previously treated with an anthracycline with or without a taxane (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11197,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Talazoparib (BMN-673) treatment in pancreatic cancer patients resulted in four patients with a clinical benefit including a partial response in one patient harboring a BRCA2 mutation (PMID: 28242752).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9147,
                    "pubMedId": 28242752,
                    "title": "Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28242752"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6854,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) demonstrated preliminary efficacy in metastatic breast cancer patients, with partial response in 25% (4/16) and stable disease in 62.5% (10/16) of patients with BRCA1/2 mutations or Fanconi Anemia pathway defects (J Clin Oncol 32:5s, 2014 (suppl; abstr 1074)).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 2704,
                "therapyName": "Carboplatin + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5878,
                    "pubMedId": null,
                    "title": "Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).",
                    "url": "http://meetinglibrary.asco.org/content/132155-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13147,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CX-5461 treatment resulted in partial response in a patient with advanced solid tumor harboring BRCA2 mutations, and stable disease in 5 additional patients, 4 of whom harboring BRCA1/2 mutations, and 1 with Li-Fraumeni syndrome (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 440; NCT02719977).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10991,
                    "pubMedId": null,
                    "title": "A phase 1 trial evaluating CX-5461 in patients with advanced solid tumors",
                    "url": "https://academic.oup.com/annonc/article/29/suppl_3/mdy048.003/4917515"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20815,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Zejula (niraparib) treatment resulted in a partial response with a median response duration of 387 days in 40% (8/20) of patients with BRCA1- or BRCA2-mutated ovarian or primary peritoneal cancer (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 1725,
                "name": "peritoneum cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6855,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Veliparib (ABT-888) demonstrated preliminary clinical activity in patients with BRCA2-mutant metastatic castration resistant prostate cancer, with an overall response rate of 66% (2/3) and clinical benefit rate of 100% (3/3) (J Clin Oncol 33, 2015 (suppl 7; abstr 170)).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5880,
                    "pubMedId": null,
                    "title": "Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).",
                    "url": "http://meetinglibrary.asco.org/content/141499-159"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17713,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline BRCA1/2 mutations are associated with increased risk of developing prostate cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11201,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Talzenna (talazoparib) treatment in patients with triple-receptor negative breast cancer carrying a BRCA1 and/or BRCA2 mutation (n=9) resulted in a clinical benefit rate of 56% and a median progression-free survival of 20.4 weeks (PMID: 28242752).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9147,
                    "pubMedId": 28242752,
                    "title": "Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28242752"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17487,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Talzenna (talazoparib) is included in guidelines for triple-receptor negative breast cancer patients with BRCA mutations who were previously treated with an anthracycline with or without a taxane (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17708,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Platinol (cisplatin), in combination with Gemzar (gemcitabine), is included in guidelines as a first-line therapy for advanced or metastatic pancreatic adenocarcinoma patients with BRCA2 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 1467,
                "therapyName": "Cisplatin + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17705,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "FOLFIRINOX is included in guidelines as a first-line therapy for advanced or metastatic pancreatic adenocarcinoma patients with BRCA2 mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 1903,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin",
                "synonyms": "FOLFIRINOX|FOLFOXIRI"
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6520,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ABT-767 treatment resulted in a response rate of 18% (n=14/79) in patients with high grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer or with solid tumors harboring germline BRCA1 or BRCA2 mutations, with an overall 6 month time to progression rate of 22% (Ann Oncol (2014) 25 (suppl 4): iv150).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 4133,
                "therapyName": "ABT-767",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5681,
                    "pubMedId": null,
                    "title": "A STUDY OF ABT-767 IN ADVANCED SOLID TUMORS WITH BRCA 1 AND BRCA 2 MUTATIONS AND HIGH GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER",
                    "url": "http://annonc.oxfordjournals.org/content/25/suppl_4/iv150.2.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11200,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Talazoparib (BMN673) treatment in breast cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 50% (7/14), including one patient with a complete response and six patients with a partial response, and resulted in a median progression free survival of 34.6 weeks (PMID: 28242752).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9147,
                    "pubMedId": 28242752,
                    "title": "Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28242752"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17477,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Talzenna (talazoparib) is included in guidelines for breast cancer patients with BRCA mutations who progressed on endocrine therapy and were previously treated with an anthracycline with or without a taxane (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11202,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Talazoparib (BMN-673) treatment in ovarian cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 48%, including one complete response, and a clinical benefit rate of 76% at 24 weeks (PMID: 28242752).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9147,
                    "pubMedId": 28242752,
                    "title": "Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28242752"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20809,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with pancreatic cancer harboring a BRCA2 mutation was refractory to Zejula (niraparib) treatment (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14034,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study of a Phase III trial, ovarian carcinoma patients harboring a mutation in either BRCA1, BRCA2, or another homologous recombination repair (HRR) gene did not demonstrate a significant difference in progression free survival when Avastin (bevacizumab) was added to the combined platinum therapy, Platinol (carboplatin) and Taxol (paclitaxel), versus the platinum therapy with placebo, suggesting HRR gene mutations do not impact the effect of Avastin (bevacizumab) (PMID: 29191972).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 1152,
                "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11433,
                    "pubMedId": 29191972,
                    "title": "Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29191972"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17383,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Lynparza (olaparib) is included in the guidelines as a maintenance therapy following response to a platinum-based therapy in ovarian cancer patients with BRCA mutations (ESMO.org; PMID: 31046081).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15114,
                    "pubMedId": 31046081,
                    "title": "ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31046081"
                },
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6744,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Rubraca (rucaparib) treatment resulted in an objective response rate of 11% (2/19) and a disease control rate of 32% (6/19) in advanced pancreatic cancer patients with a known deleterious BRCA mutation, of whom 79% harbored a BRCA2 mutation (J Clin Oncol 34, 2016 (suppl; abstr 4110)).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5806,
                    "pubMedId": null,
                    "title": "RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.",
                    "url": "http://meetinglibrary.asco.org/content/166810-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20811,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Zejula (niraparib) was well-tolerated and demonstrated preliminary efficacy in advanced solid tumor patients, including partial responses in 50% (2/4) of breast cancer patients carrying BRCA1 or BRCA2 mutations (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13733,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline BRCA1/2 mutations are associated with increased risk of developing and early onset of pancreatic cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20808,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with prostate cancer harboring a BRCA2 mutation was refractory to Zejula (niraparib) treatment (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12603,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ARIEL3), Rubraca (rucaparib) treatment resulted in significantly improved progression-free survival compared to placebo (16.6 vs 5.4 months, HR=0.23, p=0.0001) in patients with BRCA-mutant, platinum-sensitive ovarian cancer (PMID: 28916367; NCT01968213).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10475,
                    "pubMedId": 28916367,
                    "title": "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28916367"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8867,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Rubraca (rucaparib) was tolerated and demonstrated activity in ovarian cancer patients with germline BRCA1/2 mutations (PMID: 27002934).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6778,
                    "pubMedId": 27002934,
                    "title": "Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27002934"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19481,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 and Lynparza (olaparib) combination treatment inhibited viability of triple-negative breast cancer cells harboring wild-type ATM in culture, and induced tumor regression in a patient-derived xenograft (PDX) model harboring wild-type ATM, TP53 and BRCA2 mutations, CCNE1 amplification, and CDKN2A deletion (PMID: 31699977).",
            "molecularProfile": {
                "id": 34749,
                "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut"
            },
            "therapy": {
                "id": 8902,
                "therapyName": "AZD7648 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19472,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 treatment inhibited tumor growth, however, with decreased response compared to AZD7648 and Doxil (pegylated liposomal-doxorubicin) combination in a patient-derived xenograft (PDX) model of triple-negative breast cancer harboring TP53 and BRCA2 mutations, CCNE1 amplification, CDKN2A deletion, and wild-type ATM (PMID: 31699977).",
            "molecularProfile": {
                "id": 34749,
                "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut"
            },
            "therapy": {
                "id": 8900,
                "therapyName": "AZD7648",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19471,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 and Doxil (pegylated liposomal-doxorubicin) combination treatment synergistically inhibited tumor growth in a patient-derived xenograft (PDX) model of triple-negative breast cancer harboring TP53 and BRCA2 mutations, CCNE1 amplification, CDKN2A deletion, and wild-type ATM (PMID: 31699977).",
            "molecularProfile": {
                "id": 34749,
                "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut"
            },
            "therapy": {
                "id": 8901,
                "therapyName": "AZD7648 + Pegylated liposomal-doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20446,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Fluzoparib treatment inhibited proliferation of breast cancer cells harboring a BRCA2 mutation and BRCA1 deficiency in culture (PMID: 30663191).",
            "molecularProfile": {
                "id": 35178,
                "profileName": "BRCA1 loss BRCA2 mut"
            },
            "therapy": {
                "id": 9101,
                "therapyName": "Fluzoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17840,
                    "pubMedId": 30663191,
                    "title": "Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30663191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20449,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Fluzoparib treatment sensitized BRCA1 deficient and BRCA2 mutant breast cancer cells to Temodar (temozolomide), and synergistically inhibited proliferation in culture, and inhibited tumor growth and induced partial regression in a cell line xenograft model (PMID: 30663191).",
            "molecularProfile": {
                "id": 35178,
                "profileName": "BRCA1 loss BRCA2 mut"
            },
            "therapy": {
                "id": 9363,
                "therapyName": "Fluzoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17840,
                    "pubMedId": 30663191,
                    "title": "Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30663191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1206,
            "profileName": "BRCA2 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27914,
            "profileName": "BRCA2 mut ERBB2 neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34553,
            "profileName": "ATM wild-type BRCA2 mut CCNE1 amp CDKN2A del TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34749,
            "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35178,
            "profileName": "BRCA1 loss BRCA2 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}